		Fax Refe	ury Specialty Script erral To: 877-521-5353	CENTURY SPECIALTY SCRIPT.											
Date:			ne: 800-521-3949												
Patient Information Please complete the following or send patient demographic she Patient Name:			Prescriber Name: Address:	escriber Information											
			City, State, Zip:	City, State, Zip:											
				Phone:Fax:											
			DEA:	DEA:NPI#:											
Cell Phone:			Contact Person:												
DOB:	Gender:	]M □F													
		Insuran	ice Information												
Primary Insurance:															
			ID#:Group:												
•	ance: rd: ID#:		BIN#: PCN#:	D#:Group:											
Prescription Car						-1)									
	al Information (Section mus on Insurance Number:	t be completed t	o process prescription)	(Attach separate sheet if	neeae	a)									
	ease include diagnosis name	with ICD-10 co	de Therapy Details:	lew □ Reauthorization □ Re	estart										
Diagnosis					Jotan										
🗆 K50.00 Crohr	n's disease of small intestines wi	thout complication	ons Weight k	g/lbs Height		cm/in									
	's disease of both intestines with	•	· · · · · · · · · · · · · · · · · · ·	· · · · · ·											
	n's disease of large intestines wit		•												
	n's disease, unspecified, witho			Lab Data Prior Therapies											
	nophilic Esophagitis	areempheader													
			Concomitant Medications Additional Comments												
Other diagnosis: ICD-10 code      DescriptionDate of Description			—												
Has a TB test be															
	t have an active infection?														
StartDate	Review Date														
StartDate		Prescrin	tion Information												
Medication	on Dose Strength Directions					Refills									
		g/mL Starter Ki		pading Dose: Inject 400mg SC at Weeks 0, 2, and 4											
	□ 200mg/mL prefilled Syringe		Maintenance Dose: Inject												
□ Dupixent	□ PFS with needle shield 30 □ Prefilled Pen 300 mg/2 mL		□ Inject 300 mg Sub Q every week												
🗆 Entyvio	🗆 300mg vial		□ Loading Dose: Inject 300n	ng IV over 30 minutes at											
Weeks 0, 2, and 6.															
			□ Maintenance Dose: Infuse	300mg IV over 30 minutes											
<u> </u>			every 8 weeks												
🗆 Humira	Starter Kits:		Adult: Loading Dose: Inject 160m	a SC on Day 1 than 90mg											
Adalimumab (biosimilar)	80mg/0.8mL Starter Pack Pre-Filled	Pen (Cillate Free)	on Day 15 (two weeks la												
(biosiriiiar)	40mg/0.4mLPre-FilledPen(Citrate	e Free)	□ Maintenance Dose: Inject 40mg SC every other week												
40mg/0.4mLPre-Filled Syringe (Citrate Free)			(starting Day 29)												
	Other:		Pediatric (>6 years and adolescents) 17kg to < 40kg												
□ Loading Dose: Inject 80mg SC on Day 1, 40mg															
			15 (two weeks later) <b>Maintenance Dose:</b> Inject 20mg SC every other week												
			(starting Day 29)	zonigoceveryourierweek											
			Pediatric (>6 years and adolescents) > 40kg □ Loading Dose: Inject 160mg SC on Day 1, 80mg on Day 15 (two weeks later)												
											Maintenance Dose: Inject 40mg SC every other week				
											(starting Day 29)				
PrescriberSign			Dispense as Written) 🛛 🗆 Y	□ N Date:											

The information contained in this facsimile may be confidential and is intended solely for the use of the named recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intend recipient, please notify us immediately by calling or faxing back to the originator.

Crohn's and Ulcerative Colitis Referral Form		Century Specialty Script Fax Referral To: 877-521-5353		3		r			
Date: Pho			ne: 800-521-3949			SCAF			
Patient Information Please complete the following or send patient demographic sh Patient Name:			Address:						
Address:				City, State, Zip: Phone: Fax:					
Cell Phone:				DEA:NPI#: Contact Person:					
		Insura	nce l	nformation					
Primary Insurance: Secondary Insurance: Prescription Card: ID#:			I	Group:					
•				BIN#:PCN#:Group:					
	ical Information (Section mus	-	-			(Attach separate sheet if	neede	ed)	
	ation Insurance Number: Please include diagnosis name				s:⊡Ne	w $\Box$ Reauthorization $\Box$ Re	estart		
<ul> <li>K50.00 Crohn's disease of small intestines without complicati</li> <li>K50.8 Crohn's disease of both intestines without complication</li> <li>K50.10 Crohn's disease of large intestines without complication</li> <li>K50.00 Crohn's disease, unspecified, without complication</li> <li>Other diagnosis: ICD-10 code</li> <li>Description Date of Description</li> <li>Has a TB test been performed?</li> <li>Yes</li> <li>Does the Patient have an active infection?</li> </ul>			ions ions ns No	Weightkg/lbs Heightcm/in         Allergies         Lab Data         Prior Therapies         Concomitant Medications         Additional Comments         Injection Training Required?					
	Review Date		0						
			otion	Information					
Medication	Dose Strength	Trescrip			Directio	ons	Qty	Refills	
☐ Avsola ☐ Inflectra ☐ Remicade ☐ Renflexis	□ 100mg Vial		□ M	Loading Dose: Infuse 5mg/kg at Weeks 0, 2, and 6     Maintenance Dose: Infuse 5mg/kg every 8 weeks				Reilij	
□ Rinvoq	<ul> <li>Induction Therapy – 45 mg tablet</li> <li>Maintenance Therapy – 15 mg or 30 mg tablets</li> </ul>		<ul> <li>Induction Therapy: 45 mg PO daily x 8 weeks.</li> <li>Maintenance Therapy:</li> <li>15 mg PO daily</li> <li>30 mg PO daily</li> </ul>						
🗆 Simponi	□ 100mg/mL SmartJect Auto □ 100mg/mL Prefilled Syringe								
□ Stelara	□ 130mg/26mL solution single □ 90mg/mL Prefilled Syringe Date of Initial Infusion:								
□ Skyrizi	use vial. D Ongoing Therapy – 360 mg/2.4 mL			<ul> <li>□ Initiation Therapy – □ Inject 600 mg IV over at least 1 nour at Weeks 0, 4, 8. 1vial/week.</li> <li>□ Ongoing Therapy – Week 12 – Inject 360 mg SC and every 8 weeks thereafter. 1 device with prefilled cartridge.</li> </ul>					
□ Xeljanz	<ul> <li>5mg tablet</li> <li>10mg tablet</li> <li>11mgXRtablet</li> <li>22mgXRtablet</li> </ul>			aintenance Dose:	□ XR: : □ 5m once d	g twice daily 🗆 XR: 22mg			
Prescriber Sigr	nature:	DAW (I	Dispe	nseas Written)	<b>□Y</b> [	N Date:			

The information contained in this facsimile may be confidential and is intended solely for the use of the named recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intend recipient, please notify us immediately by calling or faxing back to the originator.